These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23058884)

  • 1. Discovery of novel pyrrolopyridazine scaffolds as transient receptor potential vanilloid (TRPV1) antagonists.
    Dorange I; Forsblom R; Macsari I; Svensson M; Bylund J; Besidski Y; Blid J; Sohn D; Gravenfors Y
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6888-95. PubMed ID: 23058884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent transient receptor potential vanilloid 1 antagonists: design and synthesis of phenoxyacetamide derivatives.
    Takahashi E; Hirano N; Nagahara T; Yoshikawa S; Momen S; Yokokawa H; Hayashi R
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3154-6. PubMed ID: 23632270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain.
    Culshaw AJ; Bevan S; Christiansen M; Copp P; Davis A; Davis C; Dyson A; Dziadulewicz EK; Edwards L; Eggelte H; Fox A; Gentry C; Groarke A; Hallett A; Hart TW; Hughes GA; Knights S; Kotsonis P; Lee W; Lyothier I; McBryde A; McIntyre P; Paloumbis G; Panesar M; Patel S; Seiler MP; Yaqoob M; Zimmermann K
    J Med Chem; 2006 Jan; 49(2):471-4. PubMed ID: 16420034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of 5-substituted and 4,5-disubstituted-2-arylamino oxazole TRPV1 antagonists.
    Perner RJ; Koenig JR; Didomenico S; Gomtsyan A; Schmidt RG; Lee CH; Hsu MC; McDonald HA; Gauvin DM; Joshi S; Turner TM; Reilly RM; Kym PR; Kort ME
    Bioorg Med Chem; 2010 Jul; 18(13):4821-9. PubMed ID: 20570528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrido[2,3-b]pyrazines, discovery of TRPV1 antagonists with reduced potential for the formation of reactive metabolites.
    Hodgetts KJ; Blum CA; Caldwell T; Bakthavatchalam R; Zheng X; Capitosti S; Krause JE; Cortright D; Crandall M; Murphy BA; Boyce S; Brian Jones A; Chenard BL
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4359-63. PubMed ID: 20615696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of pyrrolopyridazines as novel DGAT1 inhibitors.
    Fox BM; Iio K; Li K; Choi R; Inaba T; Jackson S; Sagawa S; Shan B; Tanaka M; Yoshida A; Kayser F
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6030-3. PubMed ID: 20833038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists.
    Perner RJ; DiDomenico S; Koenig JR; Gomtsyan A; Bayburt EK; Schmidt RG; Drizin I; Zheng GZ; Turner SC; Jinkerson T; Brown BS; Keddy RG; Lukin K; McDonald HA; Honore P; Mikusa J; Marsh KC; Wetter JM; George KS; Jarvis MF; Faltynek CR; Lee CH
    J Med Chem; 2007 Jul; 50(15):3651-60. PubMed ID: 17583335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent, soluble and orally active TRPV1 antagonists. Structure-activity relationships of a series of isoxazoles.
    Ratcliffe P; Abernethy L; Ansari N; Cameron K; Clarkson T; Dempster M; Dunn D; Easson AM; Edwards D; Everett K; Feilden H; Ho KK; Kultgen S; Littlewood P; Maclean J; McArthur D; McGregor D; McLuskey H; Neagu I; Nimz O; Nisbet LA; Ohlmeyer M; Palin R; Pham Q; Rong Y; Roughton A; Sammons M; Swanson R; Tracey H; Walker G
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4652-7. PubMed ID: 21723725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.
    Blum CA; Caldwell T; Zheng X; Bakthavatchalam R; Capitosti S; Brielmann H; De Lombaert S; Kershaw MT; Matson D; Krause JE; Cortright D; Crandall M; Martin WJ; Murphy BA; Boyce S; Jones AB; Mason G; Rycroft W; Perrett H; Conley R; Burnaby-Davies N; Chenard BL; Hodgetts KJ
    J Med Chem; 2010 Apr; 53(8):3330-48. PubMed ID: 20307063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of phenylpropanamides as novel transient receptor potential vanilloid 1 antagonists.
    Li FN; Kim NJ; Nam YH; Kim SH; Seo SY; Jeong YS; Kim SY; Park YH; Suh YG
    Arch Pharm Res; 2009 Sep; 32(9):1201-10. PubMed ID: 19784574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triazine-based vanilloid 1 receptor open channel blockers: design, synthesis, evaluation, and SAR analysis.
    Vidal-Mosquera M; Fernández-Carvajal A; Moure A; Valente P; Planells-Cases R; González-Ros JM; Bujons J; Ferrer-Montiel A; Messeguer A
    J Med Chem; 2011 Nov; 54(21):7441-52. PubMed ID: 21950613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of indole-based peptoids as potent noncompetitive antagonists of transient receptor potential vanilloid 1.
    Quintanar-Audelo M; Fernández-Carvajal A; Van Den Nest W; Carreño C; Ferrer-Montiel A; Albericio F
    J Med Chem; 2007 Nov; 50(24):6133-43. PubMed ID: 17985859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.
    Hynes J; Wu H; Kempson J; Duan JJ; Lu Z; Jiang B; Stachura S; Tokarski JS; Sack JS; Khan JA; Lippy JS; Zhang RF; Pitt S; Shen G; Gillooly K; McIntyre K; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; Fura A; Schieven GL; Pitts WJ; Wrobleski ST
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3101-3106. PubMed ID: 28539220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heteroaryl beta-tetralin ureas as novel antagonists of human TRPV1.
    Jetter MC; Youngman MA; McNally JJ; McDonnell ME; Zhang SP; Dubin AE; Nasser N; Codd EE; Flores CM; Dax SL
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6160-3. PubMed ID: 17892935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trisubstituted pyrimidines as transient receptor potential vanilloid 1 (TRPV1) antagonists with improved solubility.
    Wang X; Chakrabarti PP; Ognyanov VI; Pettus LH; Tamir R; Tan H; Tang P; Treanor JJ; Gavva NR; Norman MH
    Bioorg Med Chem Lett; 2007 Dec; 17(23):6539-45. PubMed ID: 17937985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and synthesis of 6,7,8,9-tetrahydro-5H-pyrimido-[4,5-d]azepines as novel TRPV1 antagonists.
    Hawryluk NA; Merit JE; Lebsack AD; Branstetter BJ; Hack MD; Swanson N; Ao H; Maher MP; Bhattacharya A; Wang Q; Freedman JM; Scott BP; Wickenden AD; Chaplan SR; Breitenbucher JG
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7137-41. PubMed ID: 20947352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of novel diarylalkyl amides as TRPV1 antagonists.
    Li FN; Kim NJ; Paek SM; Kwon DY; Min KH; Jeong YS; Kim SY; Park YH; Kim HD; Park HG; Suh YG
    Bioorg Med Chem; 2009 May; 17(10):3557-67. PubMed ID: 19398205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of [(3)H]A-778317 to native transient receptor potential vanilloid-1 (TRPV1) channels in rat dorsal root ganglia and spinal cord.
    Bianchi BR; El Kouhen R; Chen J; Puttfarcken PS
    Eur J Pharmacol; 2010 May; 633(1-3):15-23. PubMed ID: 20153316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.
    Tamayo N; Liao H; Stec MM; Wang X; Chakrabarti P; Retz D; Doherty EM; Surapaneni S; Tamir R; Bannon AW; Gavva NR; Norman MH
    J Med Chem; 2008 May; 51(9):2744-57. PubMed ID: 18386885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1).
    Jetter MC; McNally JJ; Youngman MA; McDonnell ME; Dubin AE; Nasser N; Zhang SP; Codd EE; Colburn RW; Stone DR; Brandt MR; Flores CM; Dax SL
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2730-4. PubMed ID: 18359227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.